<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745845</url>
  </required_header>
  <id_info>
    <org_study_id>2019/287</org_study_id>
    <nct_id>NCT04745845</nct_id>
  </id_info>
  <brief_title>The Impact of Noradrenaline on Ventriculo-arterial Coupling and Central Cardiovascular Energy Delivery</brief_title>
  <official_title>The Impact of Noradrenaline on Ventriculo-arterial Coupling and Central Cardiovascular Energy Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to examine how noradrenaline in combination with venous return influences the&#xD;
      energy transmission from heart to central circulation and arteries - also called&#xD;
      arterio-ventricular coupling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study 40 elective CABG patients with written informed consent&#xD;
      will undergo assessment of their arterio-ventricular coupling postoperatively after coronary&#xD;
      bypass graft surgery. Whilst still in deep general anesthesia on the CT ICU the study&#xD;
      population will be assessed by echocardiographic examination (transthoracic and&#xD;
      transesophageal), blood pressure tracing by arterial line, respiratory data and ECG in 4&#xD;
      different situations.&#xD;
&#xD;
      Initially the individual patient is either considered fluid responsive (SVV &gt;13%) og non-&#xD;
      responsive (SVV&lt;13%) by using stroke volume variation assessed by echocardiography.&#xD;
&#xD;
      In case of fluid responsiveness a fluid bolus of 4ml/kg of crystalloid fluid is given until&#xD;
      SVV drops below 13% and the patient can be considered as fluid NON responder.&#xD;
&#xD;
      Right afterwards the study patient is stabilized with a baseline dose of noradrenaline (NA)&#xD;
      intravenously in a supine position (situation 1). Situation 2 will be a slight increase in NA&#xD;
      dose stabilizing mean arterial pressure in a &quot;baseline + 20mmHg&quot; state. After reversing the&#xD;
      NA dose back to base line level the patient is allowed a short period of rest to wean of drug&#xD;
      effect (4-5 x t1/2, appr. 12min). Subsequently the patient is to be placed in a 20% semi&#xD;
      upright position (Anti-Trendelenburg) causing an increase in fluid responsiveness (situation&#xD;
      3). Following a phase of equilibration the dose of NA is again titrated up to obtain a 20mmHg&#xD;
      increase in mean arterial pressure (situation 4).&#xD;
&#xD;
      There will be logging of arterial pressure curve and VTI-tracing I LVOT simultaneously&#xD;
      (ultrapower, uPWR) as well as calculation of energy delivery, cardiac power, oscillatory&#xD;
      power and -fraction and both arterial and ventricular elastance in every of those 4&#xD;
      situations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cardiac Power</measure>
    <time_frame>within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery</time_frame>
    <description>Change in Cardiac Power in reaction to both different noradrenaline doses and states of fluid responsiveness.&#xD;
By logging invasive BP curve and tracing left ventricular outflow tract Velocity Time Integral (by echocardiography) simultaneously Total and Mean Cardiac Power (Watt) can be determined. Examining the response to different NA doses relative to fluid responsiveness the effect of NA on arterio-ventricular coupling can be examined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oscillatory Power Fraction</measure>
    <time_frame>within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery</time_frame>
    <description>Change in Oscillatory Power Fraction (OPF) in reaction to both different noradrenaline doses and states of fluid responsiveness.&#xD;
By logging invasive BP curve and tracing left ventricular outflow tract Velocity Time Integral (by echocardiography) simultaneously Total Cardiac Power (TCP, Watt) and Cardiac Power Output (CPO, Watt) can be determined. By subtracting CPO from TCP, OPF (in %) can be calculated. Examining the response to different NA doses relative to fluid responsiveness the effect of NA on arterio-ventricular coupling can be examined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in single beat ventricular elastance</measure>
    <time_frame>within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery</time_frame>
    <description>Change in single beat ventricular elastance in reaction to both different noradrenaline doses and states of fluid responsiveness.&#xD;
Ventricular elastance (Ees) can be determined on the bedside by using a single beat measurement of left ventricular ejection fraction, stroke volume, preejection time and ejection time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in single beat arterial elastance</measure>
    <time_frame>within 30 minutes after having been stabilised on the cardiothoracic ICU after performed CABG surgery</time_frame>
    <description>Change in single beat arterial elastance in reaction to both different noradrenaline doses and states of fluid responsiveness. Using an estimative formula Ea can be calculated (Ea=SBPx0.9/SV) and Ea/Ees as a marker of arterio-ventricular coupling can be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Noradrenalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with 2 different NA concentrations in 2 different states of fluid responsiveness</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Noradrenalin</intervention_name>
    <description>Norepinephrine challenge (concentration 'A' ) in fluid responsive position</description>
    <arm_group_label>Noradrenalin</arm_group_label>
    <other_name>Anti-Trendelenburg position/Semiupright position (20degr)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Noradrenalin</intervention_name>
    <description>Norepinephrine challenge (concentration 'A') in non-fluid responsive position</description>
    <arm_group_label>Noradrenalin</arm_group_label>
    <other_name>supine position</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Noradrenalin</intervention_name>
    <description>Norepinephrine challenge (concentration 'B') in fluid responsive position</description>
    <arm_group_label>Noradrenalin</arm_group_label>
    <other_name>Anti-Trendelenburg position/Semiupright position (20degr)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Noradrenalin</intervention_name>
    <description>Norepinephrine challenge (concentration 'B') in non-fluid responsive position</description>
    <arm_group_label>Noradrenalin</arm_group_label>
    <other_name>supine position</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  elective coronary artery bypass graft surgery&#xD;
&#xD;
          -  requirement for Noradrenaline/Norepinephrine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lack of informed consent&#xD;
&#xD;
          -  patient unsuitable for mean arterial pressure (MAP) elevation of 20mmHg&#xD;
&#xD;
          -  patient requiring different blood pressure range due to medical/surgical needs&#xD;
&#xD;
          -  poor image quality due to patient factors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilde Pleym (Head of Department), md, PhD</last_name>
    <role>Study Director</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hans Martin Flade, md</last_name>
    <phone>004798858856</phone>
    <email>hans.m.flade@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Idar Kirkeby-Garstad, md, PhD</last_name>
    <phone>004791757579</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Olavs Hospital, Dep. for Anesthesia &amp; Intensive care. Section of cardiothoracic Anesthesia and -intensive Care.</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Martin Flade, md</last_name>
      <email>hans.m.flade@ntnu.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Noradrenaline</keyword>
  <keyword>Heart surgery</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Cardiac physiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

